Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

Trial Profile

Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seliciclib (Primary)
  • Indications Pituitary ACTH hypersecretion
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2022 Results assessing efficacy of seliciclib for the treatment of patients with Cushing's disease in two studies ( NCT02160730 and NCT03774446) published in the Journal of Clinical Endocrinology and Metabolism.
    • 06 Nov 2018 Status changed from recruiting to discontinued.
    • 24 Sep 2018 According to a Food and Drug Administration media release, USFDA awarded the trial with research grant.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top